[Effect of centrophenoxine (Lucidril ANP 235) on withdrawal syndromes in the detoxification treatment of opium, opiates, and synthetic substances with morphine effect].
D000085:Acetates / Q000627:therapeutic use*; D006801:Humans; D002504:Meclofenoxate / Q000627:therapeutic use; D009638:Norepinephrine / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000517:prevention & control; D013997:Time Factors
D000085:Acetates; D012701:Serotonin; D002504:Meclofenoxate; D009638:Norepinephrine
Action de la centrophénoxine (Lucidril ANP 235) sur le syndrome d'abstinence dans les cures de désintoxication d'opium, opiacés et substances synthétiques à effet morphinique.